Author: Nguyen, Vivian V.T.; Witwer, Kenneth W.; Verhaar, Marianne C.; Strunk, Dirk; van Balkom, Bas W.M.
Title: Functional assays to assess the therapeutic potential of extracellular vesicles Cord-id: 8skfqgil Document date: 2020_11_29
ID: 8skfqgil
Snippet: An important aspect in the development of extracellular vesicle (EV) therapeutics is identifying and quantifying the key features defining their identity, purity, sterility, potency and stability to ensure batchâ€toâ€batch reproducibility of their therapeutic efficacy. Apart from EVâ€inherent features, therapeutic efficacy depends on a variety of additional parameters, like dosing, frequency of application, and administration route, some of which can be addressed only in clinical trials. Befo
Document: An important aspect in the development of extracellular vesicle (EV) therapeutics is identifying and quantifying the key features defining their identity, purity, sterility, potency and stability to ensure batchâ€toâ€batch reproducibility of their therapeutic efficacy. Apart from EVâ€inherent features, therapeutic efficacy depends on a variety of additional parameters, like dosing, frequency of application, and administration route, some of which can be addressed only in clinical trials. Before initiating clinical trials, EVâ€inherent features should be tested in wellâ€standardized quantitative assays in vitro or in appropriate animal models in vivo. Ideally, such assays would predict if a particular EV preparation has the potential to achieve its intended therapeutic effects, and could be further developed into formal potency assays as published by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines. Furthermore, such assays should facilitate the comparison of EV preparations produced in different batches, on different manufacturing platforms or deriving from different cell sources. For now, a wide spectrum of in vitro and in vivo assays has been used to interrogate the therapeutic functions of EVs. However, many cannot accurately predict therapeutic potential. Indeed, several unique challenges make it difficult to set up reliable assays to assess the therapeutic potential of EVs, and to develop such assays into formal potency tests. Here, we discuss challenges and opportunities around in vitro and in vivo testing of EV therapeutic potential, including the need for harmonization, establishment of formal potency assays and novel developments for functional testing.
Search related documents:
Co phrase search for related documents- absence presence and accuracy sensitivity: 1, 2, 3, 4
- absence presence and actual number: 1
- absence presence and acute aki kidney injury: 1, 2, 3
- absence presence and acute ischemic stroke: 1, 2, 3, 4, 5, 6, 7
- absence presence and acute kidney injury: 1, 2, 3, 4, 5, 6, 7
- absence presence and administration route: 1
- absence presence and live imaging: 1, 2, 3
- absence presence and liver heart: 1, 2
- absence presence and liver kidney: 1, 2
- absence presence and liver spleen: 1
- absence presence and lod detection limit: 1
- absence presence and low high density: 1
- absence presence and lymphoid cell: 1, 2
- absence presence and macrophage cell line: 1
- absence presence and macrophage response: 1, 2
- absolute quantification and accuracy sensitivity: 1, 2
- absolute quantification and liver heart: 1
- absolute quantification and liver kidney: 1
- absolute quantification and lod detection limit: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date